Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-023-04803-1.pdf
Reference29 articles.
1. Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67–76. https://doi.org/10.1016/s0140-6736(16)32455-2
2. Chung HC, Ros W, Delord J-P et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37:1470–1478. https://doi.org/10.1200/jco.18.01265
3. Cioffi P, Antonelli D, Belfiglio M, Melena S, Petrelli F, Grappasonni I (2012) The impact of a pharmacist as a member of healthcare team on facilitating evidenced-based prescribing of innovative drugs in an Italian oncology department. J Oncol Pharm Pract 18:207–212. https://doi.org/10.1177/1078155211424787
4. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Bosenthal MB, Bach PB (2013) Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 31:1134–1139. https://doi.org/10.1200/jco.2012.42.7252
5. Eaton AA, Sima CS, Panageas KS (2016) Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-medicare data. J Natl Compr Cancer Netw 14:57–65. https://doi.org/10.6004/jnccn.2016.0007
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center;Cancer Medicine;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3